MORF News and Press, Morphic Holding Inc. From 04/06/22

Dr. Brihad Abhyankar named Vice President of Clinical Development, deeply experienced GI drug development leader Aaron Pelta promoted to Senior Vice President, Business and Corporate Development; leading portfolio, commercial, and partnering strategy WALTHAM, Mass., April 06, ...

WALTHAM, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced Morphic COO and CFO Marc Schegerin, M.D. will particip...

MORF-057, an oral α4β7 integrin inhibitor candidate, holds potential for treating inflammatory bowel diseases Phase 2b EMERALD-2 clinical trial of MORF-057 expected to begin mid-year 2022 WALTHAM, Mass., March 25, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeuti...

WALTHAM, Mass., March 04, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced Morphic President and CEO Praveen Tipirneni, M.D. will...

Morphic press release (NASDAQ:MORF): FY GAAP EPS of -$2.67 misses by $0.09. Revenue of $19.79M (-56.0% Y/Y) misses by $2.77M. For further details see: Morphic GAAP EPS of -$2.67 misses by $0.09, revenue of $19.79M misses by $2.77M

Presented positive Phase 1 data for MORF-057 Phase 2a trial in patients with ulcerative colitis scheduled to begin 1Q22; Phase 2b to commence mid-year Presented preclinical data from αvβ8 program at AACR and SITC demonstrating anti-tumor activity in checkpo...

New preclinical data expand understanding of α4β7- expressing immune cells and MORF-057 dose response Data support ongoing clinical development program in IBD WALTHAM, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biot...

WALTHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., President and Chief Executive...

αvβ8 inhibition demonstrates efficacy in a cancer model refractory to radiation and checkpoint inhibition Data provide increased rationale to explore integrin inhibition as a component in combination immunotherapy to drive anti-tumor response via TGFβ pathwa...

Morphic (NASDAQ:MORF): Q3 GAAP EPS of -$0.69 beats by $0.07. Revenue of $3.12M (-87.9% Y/Y) misses by $2.07M. Press Release For further details see: Morphic EPS beats by $0.07, misses on revenue